FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304633208> ?p ?o ?g. }

• W4304633208 endingPage "S306" @default.
• W4304633208 startingPage "S305" @default.
• W4304633208 abstract "ObjectivesPsilocybin-assisted therapy is currently being investigated for its therapeutic potential in the treatment of MDD in adults. This talk will review the typical therapeutic approach, along with some of the major findings in this area to date, with a focus on the results from a prospective long-term follow-up study of patients with moderate to severe depression who received 2 doses of psilocybin in a supported setting.MethodsThis randomized, waiting-list controlled study enrolled 27 patients aged 21 to 75 years with moderate to severe unipolar depression (GRID-HAMD ≥17). Participants were randomized to an immediate or delayed (8 weeks) treatment condition in which they received 2 doses of psilocybin with supportive psychotherapy. Twenty-four participants completed both psilocybin sessions and were followed through 12 months following their second dose.ResultsAll 24 participants attended all follow-up visits through the 12-month timepoint. Large decreases from baseline in GRID Hamilton Rating Scale for Depression (GRID-HAMD) scores were observed at 1-, 3-, 6-, and 12-month follow-up (Cohen d = 2.3, 2.0, 2.6, and 2.4, respectively). Treatment response (≥50% reduction in GRID-HAMD score from baseline) and remission were 75% and 58%, respectively, at 12 months. There were no serious adverse events judged to be related to psilocybin in the long-term follow-up period, and no participants reported psilocybin use outside of the context of the study. Participant ratings of personal meaning, spiritual experience, and mystical experience after the sessions predicted increased well-being at 12 months but did not predict improvement in depression. One-third of the participants began treatment with an antidepressant medication during the follow-up period.ConclusionsThese findings demonstrate that the substantial antidepressant effects of psilocybin-assisted therapy may be durable at least through 12 months following acute intervention in some patients. Contextual factors and psychotherapy likely play a substantial role in the safety and efficacy of the treatment and will require careful consideration if this intervention is studied in younger patient populations.DDD, PTA, PSP ObjectivesPsilocybin-assisted therapy is currently being investigated for its therapeutic potential in the treatment of MDD in adults. This talk will review the typical therapeutic approach, along with some of the major findings in this area to date, with a focus on the results from a prospective long-term follow-up study of patients with moderate to severe depression who received 2 doses of psilocybin in a supported setting. Psilocybin-assisted therapy is currently being investigated for its therapeutic potential in the treatment of MDD in adults. This talk will review the typical therapeutic approach, along with some of the major findings in this area to date, with a focus on the results from a prospective long-term follow-up study of patients with moderate to severe depression who received 2 doses of psilocybin in a supported setting. MethodsThis randomized, waiting-list controlled study enrolled 27 patients aged 21 to 75 years with moderate to severe unipolar depression (GRID-HAMD ≥17). Participants were randomized to an immediate or delayed (8 weeks) treatment condition in which they received 2 doses of psilocybin with supportive psychotherapy. Twenty-four participants completed both psilocybin sessions and were followed through 12 months following their second dose. This randomized, waiting-list controlled study enrolled 27 patients aged 21 to 75 years with moderate to severe unipolar depression (GRID-HAMD ≥17). Participants were randomized to an immediate or delayed (8 weeks) treatment condition in which they received 2 doses of psilocybin with supportive psychotherapy. Twenty-four participants completed both psilocybin sessions and were followed through 12 months following their second dose. ResultsAll 24 participants attended all follow-up visits through the 12-month timepoint. Large decreases from baseline in GRID Hamilton Rating Scale for Depression (GRID-HAMD) scores were observed at 1-, 3-, 6-, and 12-month follow-up (Cohen d = 2.3, 2.0, 2.6, and 2.4, respectively). Treatment response (≥50% reduction in GRID-HAMD score from baseline) and remission were 75% and 58%, respectively, at 12 months. There were no serious adverse events judged to be related to psilocybin in the long-term follow-up period, and no participants reported psilocybin use outside of the context of the study. Participant ratings of personal meaning, spiritual experience, and mystical experience after the sessions predicted increased well-being at 12 months but did not predict improvement in depression. One-third of the participants began treatment with an antidepressant medication during the follow-up period. All 24 participants attended all follow-up visits through the 12-month timepoint. Large decreases from baseline in GRID Hamilton Rating Scale for Depression (GRID-HAMD) scores were observed at 1-, 3-, 6-, and 12-month follow-up (Cohen d = 2.3, 2.0, 2.6, and 2.4, respectively). Treatment response (≥50% reduction in GRID-HAMD score from baseline) and remission were 75% and 58%, respectively, at 12 months. There were no serious adverse events judged to be related to psilocybin in the long-term follow-up period, and no participants reported psilocybin use outside of the context of the study. Participant ratings of personal meaning, spiritual experience, and mystical experience after the sessions predicted increased well-being at 12 months but did not predict improvement in depression. One-third of the participants began treatment with an antidepressant medication during the follow-up period. ConclusionsThese findings demonstrate that the substantial antidepressant effects of psilocybin-assisted therapy may be durable at least through 12 months following acute intervention in some patients. Contextual factors and psychotherapy likely play a substantial role in the safety and efficacy of the treatment and will require careful consideration if this intervention is studied in younger patient populations.DDD, PTA, PSP These findings demonstrate that the substantial antidepressant effects of psilocybin-assisted therapy may be durable at least through 12 months following acute intervention in some patients. Contextual factors and psychotherapy likely play a substantial role in the safety and efficacy of the treatment and will require careful consideration if this intervention is studied in younger patient populations." @default.
• W4304633208 created "2022-10-12" @default.
• W4304633208 creator A5048292874 @default.
• W4304633208 date "2022-10-01" @default.
• W4304633208 modified "2023-10-17" @default.
• W4304633208 title "19.3 Psilocybin-Assisted Therapy for MDD: Current Evidence and Clinical Considerations" @default.
• W4304633208 doi "https://doi.org/10.1016/j.jaac.2022.07.664" @default.
• W4304633208 hasPublicationYear "2022" @default.
• W4304633208 type Work @default.
• W4304633208 citedByCount "0" @default.
• W4304633208 crossrefType "journal-article" @default.
• W4304633208 hasAuthorship W4304633208A5048292874 @default.
• W4304633208 hasConcept C118552586 @default.
• W4304633208 hasConcept C124315065 @default.
• W4304633208 hasConcept C126322002 @default.
• W4304633208 hasConcept C139719470 @default.
• W4304633208 hasConcept C151730666 @default.
• W4304633208 hasConcept C15744967 @default.
• W4304633208 hasConcept C162324750 @default.
• W4304633208 hasConcept C168563851 @default.
• W4304633208 hasConcept C197934379 @default.
• W4304633208 hasConcept C2776466505 @default.
• W4304633208 hasConcept C2776502132 @default.
• W4304633208 hasConcept C2776867660 @default.
• W4304633208 hasConcept C2777198177 @default.
• W4304633208 hasConcept C2779343474 @default.
• W4304633208 hasConcept C2780051608 @default.
• W4304633208 hasConcept C2780733359 @default.
• W4304633208 hasConcept C558461103 @default.
• W4304633208 hasConcept C70410870 @default.
• W4304633208 hasConcept C71924100 @default.
• W4304633208 hasConcept C86803240 @default.
• W4304633208 hasConceptScore W4304633208C118552586 @default.
• W4304633208 hasConceptScore W4304633208C124315065 @default.
• W4304633208 hasConceptScore W4304633208C126322002 @default.
• W4304633208 hasConceptScore W4304633208C139719470 @default.
• W4304633208 hasConceptScore W4304633208C151730666 @default.
• W4304633208 hasConceptScore W4304633208C15744967 @default.
• W4304633208 hasConceptScore W4304633208C162324750 @default.
• W4304633208 hasConceptScore W4304633208C168563851 @default.
• W4304633208 hasConceptScore W4304633208C197934379 @default.
• W4304633208 hasConceptScore W4304633208C2776466505 @default.
• W4304633208 hasConceptScore W4304633208C2776502132 @default.
• W4304633208 hasConceptScore W4304633208C2776867660 @default.
• W4304633208 hasConceptScore W4304633208C2777198177 @default.
• W4304633208 hasConceptScore W4304633208C2779343474 @default.
• W4304633208 hasConceptScore W4304633208C2780051608 @default.
• W4304633208 hasConceptScore W4304633208C2780733359 @default.
• W4304633208 hasConceptScore W4304633208C558461103 @default.
• W4304633208 hasConceptScore W4304633208C70410870 @default.
• W4304633208 hasConceptScore W4304633208C71924100 @default.
• W4304633208 hasConceptScore W4304633208C86803240 @default.
• W4304633208 hasIssue "10" @default.
• W4304633208 hasLocation W43046332081 @default.
• W4304633208 hasOpenAccess W4304633208 @default.
• W4304633208 hasPrimaryLocation W43046332081 @default.
• W4304633208 hasRelatedWork W1889807169 @default.
• W4304633208 hasRelatedWork W1920207017 @default.
• W4304633208 hasRelatedWork W1979385243 @default.
• W4304633208 hasRelatedWork W2016853339 @default.
• W4304633208 hasRelatedWork W2035812333 @default.
• W4304633208 hasRelatedWork W2135801008 @default.
• W4304633208 hasRelatedWork W2377656765 @default.
• W4304633208 hasRelatedWork W2388390772 @default.
• W4304633208 hasRelatedWork W3170813123 @default.
• W4304633208 hasRelatedWork W4212903385 @default.
• W4304633208 hasVolume "61" @default.
• W4304633208 isParatext "false" @default.
• W4304633208 isRetracted "false" @default.
• W4304633208 workType "article" @default.